Faget Quoted on FDA’s Decision to Stop Reviewing COVID-19 Lab Tests

Of Counsel Kyle Faget was quoted in a BioCentury article, “FDA to stop reviewing COVID-19 lab tests, raising concerns in Congress,” about the FDA’s announcement that it will no longer review emergency use authorization requests for laboratory developed tests to diagnose COVID-19.

The article cites an Aug. 24 blog post by Faget, who wrote that bringing an LDT to market without securing FDA premarket approval or clearance of, or an emergency use authorization (EUA), comes at a steep cost to clinical laboratories. “Public Health and Emergency Preparedness Act (PREP Act) protection is not available to clinical laboratories opting to use LDTs without FDA premarket review or authorization,” she wrote.

Partner

[email protected]

Boston 617.502.3292

Related News

View All Posts

01 January 2025 In the News

Faget Quoted on FDA’s Decision to Stop Reviewing COVID-19 Lab Tests

People

Kyle Y. Faget

Related News

Lauren Loew Highlights Illinois Genetic Privacy Law as Topic to Watch in 2025

Dennis Cardoza Highlights Key Energy Policy Focuses in 2025

Jeffery Atkin Shares Insight on Energy Sector Trends for 2025